Yes, Multiple System Atrophy (MSA) is widely considered a terminal illness because it is a rapidly progressive and fatal neurodegenerative disorder for which there is currently no cure.
MSA is a terminal disease with an average patient survival of 6 to 10 years after the onset of symptoms.
MSA is a permanent condition that lasts the rest of a person's life. The average survival time for this condition is six to 10 years. In less severe cases, people can survive up to 15 years. However, in very severe cases, survival time may be much lower.
People living with MSA may experience periods of low mood, depression and/or anxiety, yet mental health is often overlooked at routine appointments with health and care professionals. Being able to recognise how MSA is affecting your mental health can help you to seek professional support when needed.
A diagnosis of definite MSA is not possible until the postmortem examination is performed. However, research has allowed for advances in diagnostic assessments to aid in clinical diagnosis and enhance patient care. Multiple system atrophy (MSA) has 4 stages, each with varying symptoms across patients.
People typically live about 7 to 10 years after multiple system atrophy symptoms first appear. However, the survival rate with MSA varies widely. Death is often due to trouble breathing, infections or blood clots in the lungs.
Symptoms tend to appear in a person's 50s and advance rapidly over the course of five to 10 years. A person with MSA will have increased difficulty with movement and eventually become bedridden. People with MSA often develop swallowing problems that can lead to pneumonia in the later stages of the disease.
Appetite reduces and weight loss is apparent. Communication becomes too effortful and breathing more bubbly or shallow. Dying is a natural process where our bodily functions all slow down and ultimately stop. This will be a very emotional time for everyone close to the dying person.
Multiple system atrophy (MSA) is a rare and aggressive neurodegenerative disease that typically leads to death 6 to 10 years after symptom onset.
Anxiety, agitation, apathy, impulse control disorders, and REM sleep behavioral disorder (RBD) are the most common behavioral changes in MSA [13,14,15]. Obsessive compulsive disorders (OCD) may also occur, but these are less common [16].
Offer to do the shopping. Help with everyday tasks round the house such as hanging the washing out, doing the hoovering etc. Share your computer and technology skills with them, these can be a lifeline for people with MSA but they may need help learning to use them.
Multiple system atrophy- parkinsonian type (MSA-P) is a rare condition that causes symptoms similar to Parkinson disease. However, people with MSA-P have more widespread damage to the part of the nervous system that regulates important functions such as heart rate, blood pressure, and sweating.
Prevalence of Pain in MSA
Pooling the results of all studies included in the quantitative analysis, 761 of the 1236 individuals with MSA complained about pain, with a prevalence range of 40% to 88% and an estimated pooled prevalence of 67% (95% CI = 57%–75%) (Fig. 2).
We all enjoy going to see family, friends and having holidays, so don't let MSA stop you getting out and about and travelling if that is what you enjoy and wish to do. The key to undertaking any journey is planning.
Similar to patients with Parkinson's disease (PD) [2], [3], MSA patients frequently experience painful sensations. Up to 70% of MSA patients report pain [4], [5]. The types of pain in MSA have been described and categorized using selected and non-dedicated questionnaires [4], [5].
During the final stages of the disease, patients have trouble chewing, swallowing, speaking and breathing.
In people with MSA, nerves in the area of the brain that controls things like balance and movement become damaged and lost over time. It's not known why this happens. There's no evidence that it can be passed on to children by their parents (inherited).
In summary, all patients with MSA died from disease‐related events, with sudden death and infections being the most common. We propose that careful screening for laryngeal stridor, neurogenic bladder dysfunction and dysphagia with aggressive treatment may increase total survival time in patients with MSA.
Medicines that treat Parkinson's disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements.
Most commonly people with MSA experience increasing sluggishness of the bowel and risk a build-up of chronic constipation. You should aim to keep your bowel movements at least as regular as they were before you had MSA.
Mild cognitive impairment has been reported in up to 40 % of MSA patients6, 14 and can also occur in early stage of disease. Nonetheless, severe cognitive decline that significantly disrupts daily living is uncommon in MSA.
In Parkinsons disease and multiple system atrophy (MSA), cardiovascular dysfunction may occur for a variety of reasons and may manifest itself through inappropriate changes and/or levels in blood pressure, heart rate and/or regional vascular perfusion in a range of situations.
Respiratory symptoms, including stridor, sleep-disordered breathing, and respiratory insufficiency, are known to additionally occur in MSA,1-3 although these are not included in the consensus diagnostic criteria.
Clinicians should be aware that the following features may be 'red flags', or warning signs, of MSA-P: early instability, rapid progression, abnormal postures, bulbar dysfunction, respiratory dysfunction, and emotional incontinence.
Inheritance. Most cases of multiple system atrophy are sporadic, which means they occur in people with no history of the disorder in their family. Rarely, the condition has been reported to run in families; however, it usually does not have a clear pattern of inheritance.